. Author manuscript; available in PMC: 2022 Apr 1.

Published in final edited form as: Am J Perinatol. 2019 Oct 10;38(5):469–476. doi: 10.1055/s-0039-1698457

Table 3.

Comparison of Anti-Epileptic Medication Utilization in 2007 vs. 2016.

Entire Cohort	Neonatal period anticonvulsant therapy^a		2007	2016	P-value
			n = 191	n = 323	P-value
		Phenobarbital	185 (96.9)	295 (91.3)	0.015
		Levetiracetam	15 (7.9)	128 (39.6)	<0.0001
		Fosphenytoin/Phenytoin	33 (17.3)	67 (20.7)	0.337
		Other^b	9 (4.7)	26 (8.1)	0.146
			n =139	n = 235
	Discharged on anticonvulsant therapy	Phenobarbital	126 (90.7)	158 (67.2)	<0.0001
		Levetiracetam	14 (10.1)	120 (51.1)	<0.0001
		Fosphenytoin/Phenytoin	6 (4.3)	2 (0.9)	0.025
		Other^b	6 (4.3)	15 (6.4)	0.401
		Fosphenytoin/Phenytoin	0 (0)	1 (3.7)	0.731
		Other^b	0 (0)	1 (3.7)	0.731

Administered within the first 28 days of life.

Pyridoxine (B6), topiramate, oxcarbazepine, gabapentin, valproic acid, and carbamazepine